Behavioral, Epidemiological & Behavioral Sciences, FHI 360, 359 Blackwell Street, Durham, NC, 27701, USA.
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
AIDS Behav. 2020 Sep;24(9):2520-2531. doi: 10.1007/s10461-020-02808-2.
Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among HIV-uninfected males and females in sequentially-enrolled cohorts of two dosing strategies. We compared acceptability of product attributes, prevention preferences and future interest in injectable PrEP (FIIP) by region, sex-at-birth, arm and cohort and used multivariable analysis to identify FIIP determinants. Baseline injectable PrEP preferences were higher in non-U.S. sites and increased in both regions over time. In multivariable models, FIIP was most strongly associated with acceptability of product attributes, was higher in non-U.S. sites and more altruistic participants. Treatment arm and report of pain were not associated with FIIP. Injectable acceptability was highest in non-U.S. sites. Preferences for injectable versus other PrEP methods were higher among U.S. males than females, but higher among males and females in non-U.S. settings.
长效注射型 PrEP 可能是每日口服 PrEP 的替代方案，如果被证明是可接受、安全和有效的，它可以提高依从性和保护效果。HPTN 077 研究评估了两种不同给药方案下，接受注射用卡替拉韦的 HIV 阴性男性和女性的安全性、耐受性和药代动力学。我们比较了不同地区、出生性别、试验组和试验队列对产品属性、预防偏好和未来对注射用 PrEP（FIIP）的兴趣的接受程度，并使用多变量分析来确定 FIIP 的决定因素。在基线时，非美国研究地点对注射用 PrEP 的偏好较高，且随着时间的推移，这两个地区的偏好都有所增加。在多变量模型中，FIIP 与产品属性的可接受性密切相关，在非美国研究地点更高，且更利他的参与者也更倾向于 FIIP。治疗组和疼痛报告与 FIIP 无关。在非美国研究地点，注射用 PrEP 的接受程度最高。与其他 PrEP 方法相比，美国男性对注射用 PrEP 的偏好高于女性，但在非美国地区，男性和女性对注射用 PrEP 的偏好都更高。
